Evolution of Phage Display Libraries for Therapeutic Antibody Discovery

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2023 May 24

PMID 37222232

Authors

Yang Zhang

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies (mAbs) and their derivatives have emerged as one of the most important classes of biotherapeutics in recent decades. The success of mAb is due to their high versatility, high target specificity, excellent clinical safety profile, and efficacy. Antibody discovery, the most upstream stage of the antibody development pipeline, plays a pivotal role in determination of the clinical outcome of an mAb product. Phage display technology, originally developed for peptide directed evolution, has been extensively applied to discovery of fully human antibodies due to its unprecedented advantages. The value of phage display technology has been proven by a number of approved mAbs, including several top-selling mAb drugs, derived from the technology. Since antibody phage display was first established over 30 years ago, phage display platforms have been developed to generate mAbs targeting difficult-to-target antigens and tackle the drawbacks present in in vivo antibody discovery approaches. More recently, the new generation of phage display libraries have been optimized for discovery of mAbs with "drug-like" properties. This review will summarize the principles of antibody phage display and design of three generations of antibody phage display libraries.

Citing Articles

Challenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review.

Doring S, Weller M, Reinders Y, Konthur Z, Jaeger C Antibodies (Basel). 2025; 14(1.

PMID: 39846611 PMC: 11755444. DOI: 10.3390/antib14010003.

Engineering and Bio/Nanotechnological Applications of Virus Particles.

Mateu M, Valbuena A Subcell Biochem. 2024; 105:823-878.

PMID: 39738964 DOI: 10.1007/978-3-031-65187-8_22.

Heat-sterilizable antibody mimics designed on the cold shock protein scaffold from hyperthermophile Thermotoga maritima.

Amesaka H, Tachibana M, Hara M, Toya S, Nakagawa H, Matsumura H Protein Sci. 2024; 34(1):e70018.

PMID: 39724358 PMC: 11670304. DOI: 10.1002/pro.70018.

p-IgGen: a paired antibody generative language model.

Turnbull O, Oglic D, Croasdale-Wood R, Deane C Bioinformatics. 2024; 40(11).

PMID: 39520401 PMC: 11576349. DOI: 10.1093/bioinformatics/btae659.

Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins.

Stephens A, Wilkinson T BioDrugs. 2024; 38(6):769-794.

PMID: 39453540 PMC: 11530565. DOI: 10.1007/s40259-024-00682-1.

References

Fellouse F, Wiesmann C, Sidhu S . Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A. 2004; 101(34):12467-72. PMC: 515084. DOI: 10.1073/pnas.0401786101. View

Persson M, Caothien R, Burton D . Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci U S A. 1991; 88(6):2432-6. PMC: 51246. DOI: 10.1073/pnas.88.6.2432. View

Bass S, Greene R, Wells J . Hormone phage: an enrichment method for variant proteins with altered binding properties. Proteins. 1990; 8(4):309-14. DOI: 10.1002/prot.340080405. View

Jespers L, Roberts A, Mahler S, Winter G, Hoogenboom H . Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (N Y). 1994; 12(9):899-903. DOI: 10.1038/nbt0994-899. View

Virnekas B, Ge L, Pluckthun A, Schneider K, Wellnhofer G, Moroney S . Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. Nucleic Acids Res. 1994; 22(25):5600-7. PMC: 310122. DOI: 10.1093/nar/22.25.5600. View

Dominik P, Borowska M, Dalmas O, Kim S, Perozo E, Keenan R . Conformational Chaperones for Structural Studies of Membrane Proteins Using Antibody Phage Display with Nanodiscs. Structure. 2016; 24(2):300-9. PMC: 4740257. DOI: 10.1016/j.str.2015.11.014. View

Sommer A, Kopitz C, Schatz C, Nising C, Mahlert C, Lerchen H . Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors. Cancer Res. 2016; 76(21):6331-6339. DOI: 10.1158/0008-5472.CAN-16-0180. View

Kramer R, Cox F, van der Horst M, van der Oudenrijn S, Res P, Bia J . A novel helper phage that improves phage display selection efficiency by preventing the amplification of phages without recombinant protein. Nucleic Acids Res. 2003; 31(11):e59. PMC: 156736. DOI: 10.1093/nar/gng058. View

Akamatsu Y, Pakabunto K, Xu Z, Zhang Y, Tsurushita N . Whole IgG surface display on mammalian cells: Application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies. J Immunol Methods. 2007; 327(1-2):40-52. DOI: 10.1016/j.jim.2007.07.007. View

10.

Poole R, Vaidya A . Ramucirumab: first global approval. Drugs. 2014; 74(9):1047-58. DOI: 10.1007/s40265-014-0244-2. View

11.

Breitling F, Dubel S, Seehaus T, Klewinghaus I, Little M . A surface expression vector for antibody screening. Gene. 1991; 104(2):147-53. DOI: 10.1016/0378-1119(91)90244-6. View

12.

McCafferty J, Griffiths A, Winter G, Chiswell D . Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990; 348(6301):552-4. DOI: 10.1038/348552a0. View

13.

Valadon P, Perez-Tapia S, Nelson R, Guzman-Bringas O, Arrieta-Oliva H, Gomez-Castellano K . ALTHEA Gold Libraries™: antibody libraries for therapeutic antibody discovery. MAbs. 2019; 11(3):516-531. PMC: 6512909. DOI: 10.1080/19420862.2019.1571879. View

14.

Azevedo Reis Teixeira A, Erasmus M, DAngelo S, Naranjo L, Ferrara F, Leal-Lopes C . Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries. MAbs. 2021; 13(1):1980942. PMC: 8654478. DOI: 10.1080/19420862.2021.1980942. View

15.

Loset G, Sandlie I . Next generation phage display by use of pVII and pIX as display scaffolds. Methods. 2012; 58(1):40-6. DOI: 10.1016/j.ymeth.2012.07.005. View

16.

Persson H, Ye W, Wernimont A, Adams J, Koide A, Koide S . CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J Mol Biol. 2012; 425(4):803-11. PMC: 3764595. DOI: 10.1016/j.jmb.2012.11.037. View

17.

Pedraza-Escalona M, Guzman-Bringas O, Arrieta-Oliva H, Gomez-Castellano K, Salinas-Trujano J, Torres-Flores J . Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™. BMC Infect Dis. 2021; 21(1):1121. PMC: 8556770. DOI: 10.1186/s12879-021-06717-0. View

18.

Rothe C, Urlinger S, Lohning C, Prassler J, Stark Y, Jager U . The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol. 2008; 376(4):1182-200. DOI: 10.1016/j.jmb.2007.12.018. View

19.

Schliemann C, Gutbrodt K, Kerkhoff A, Pohlen M, Wiebe S, Silling G . Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Res. 2015; 3(5):547-56. DOI: 10.1158/2326-6066.CIR-14-0179. View

20.

Kosuri S, Church G . Large-scale de novo DNA synthesis: technologies and applications. Nat Methods. 2014; 11(5):499-507. PMC: 7098426. DOI: 10.1038/nmeth.2918. View